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Background: Active surveillance is an increasingly accepted approach for managing patients with germ-cell tumors
(GCTs) after an orchiectomy. Here we investigate a time-to-relapse stratiﬁcation scheme for clinical stage 1 (CS1) nonse-
minoma GCT (NSGCT) patients according to factors associated with relapse and identify a group of patients with a lower
frequency and longer time-to-relapse who may require an alternative surveillance strategy.
Patients and methods: We analyzed 266 CS1 GCT patients from the IRB-approved DFCI GCT database that exclu-
sively underwent surveillance following orchiectomy from 1997 to 2013. We stratiﬁed NSGCT patients according to pre-
dominance of embryonal carcinoma (EmbP) and lymphovascular invasion (LVI), using a 0, 1, and 2 scoring system. Cox
regression and conditional risk analysis were used to compare each NSGCT group to patients in the seminomatous
germ-cell tumor (SGCT) category. Median time-to-relapse values were then calculated among those patients who under-
went relapse. Relapse-free survival curves were generated using the Kaplan–Meier method.
Results: Fifty (37%) NSGCT and 20 (15%) SGCT patients relapsed. The median time-to-relapse was 11.5 versus 6.3
months for the SGCT and NSGCT groups, respectively. For NSGCT patients, relapse rates were higher and median time-
to-relapse faster with increasing number of risk factors (RFs). Relapse rates (%) and median time-to-relapse (months)
were 25%/8.5 months, 41%/6.8 months and 78%/3.8 months for RF0, RF1 and RF2, respectively. We found a statistically
signiﬁcant difference between SGCT and patients with one or two RFs (P < 0.001) but not between SGCT and NSGCT
RF0 (P = 0.108).
Conclusion: NSGCT patients grouped by a risk score system based on EmbP and LVI yielded three groups with distinct
relapse patterns -and patients with neither EmbP nor LVI appear to behave similar to SGCT.
Key words: nonseminoma germ-cell tumor, clinical stage 1, relapse, embryonal predominance, lymphovascular
invasion, active surveillance
introduction
Germ-cell tumors (GCTs) account for 95% of malignant
tumors of the testicle and are the most common solid tumor in
men ages 15–34 years [1]. CS1 seminoma and nonseminoma-
tous germ-cell tumor (NSGCT) have different propensities for
relapse [2–4] and 54% of NSGCTs present with clinical stage 1
(CS1) disease deﬁned as no tumor marker (TM) elevation or
radiographic evidence of disease beyond the scrotum [5, 6].
Orchiectomy cures ∼70% of NSGCT CS1 patients as 30% have
occult metastasis and relapse [2]. The management options for
CS1 NSGCT are nerve-sparing retroperitoneal lymph node
dissection (RPLND), adjuvant chemotherapy and surveillance
[6] with cure rates of 99% as salvage therapy cures nearly all
patients who relapse on surveillance [1]. Seminomatous germ-
cell tumors (SGCTs) present as CS1 in 75% of the cases and
orchiectomy cures ∼85% of these patients [3, 4]. The postorch-
iectomy management options for seminoma are adjuvant
chemotherapy, adjuvant external beam radiation and surveil-
lance with cure rates approximating 100% regardless of initial
management [7].
Active surveillance entails the periodic assessment of TMs, CT
of the abdomen and pelvis, and chest imaging in postorchiectomy
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patients, reserving additional treatment of those who relapse.
Surveillance has been deemed an effective management strategy
for CS1 GCTs even in patients with high-risk (∼50%) chance of
relapse, given the morbidity associated with primary RPLND or
adjuvant chemotherapy given avoidance of overtreatment of
those cured with orchiectomy alone and availability of successful
salvaged therapy [5, 8]. Recent modeling research has shown that
surveillance does not compromise life expectancy for patients
with either SGCT or NSGCT [9].
Surveillance guidelines for diagnostic imaging are more intense
for NSGCT than for seminoma patients given that the former has
a higher risk of recurrence and a shorter time-to-relapse. Different
pathological features identify NSGCT patients with higher risk of
relapse with lymphovascular invasion (LVI) being regarded as the
most consistent independent predictive factor of relapse [10, 11].
A high component of embryonal carcinoma is another factor
reported to be associated with risk of relapse [11, 12].
Given the beneﬁts of active surveillance, strategies that reduce
ionizing radiation exposure while preserving the outcome bene-
ﬁts of surveillance could improve the care of these patients. One
potential strategy is to stratify NSGCTs patients according to a
risk factor (RF) scoring system that optimizes surveillance fre-
quency for those with a low-risk and delayed time-to-relapse. In
the present study, we carried out a retrospective survey to estab-
lish a time-to-relapse model in the ﬁrst 2 years of surveillance
for CS1 NSGCT patients according relapse-associated RFs, with
particular emphasis on the ﬁrst 6 months.
patients andmethods
We identiﬁed 266 patients from the IRB-approved Dana-Farber Cancer
Institute (DFCI) GCT database with CS1 disease who were managed with
surveillance between 1997 and 2013. Clinical and pathological data collected
included: age at orchiectomy, orchiectomy histology, level of preoperative
TMs, presence/absence of LVI, embryonal predominance (EmbP), as well as
postorchiectomy management information for the ﬁrst 2 years and grouped
by 3-month intervals. These included: number of AP-CTs (abdomino-pelvic
computerized tomography excluding initial staging scan), TMs and follow-
up visits. The Genitourinary Pathology Division of Brigham and Women’s
Hospital/DFCI carried out central pathology review before treatment recom-
mendations, in accordance with institutional policy. A tumor was considered
embryonal predominant if this component was present at a level larger than
any other histologic type present on the sample. The frequency of surveil-
lance with CT-AP, chest X-ray and TMs was decided by the treating physi-
cians and in essence followed NCCN guidelines at relevant times [13].
The primary end point in this study was time-to-relapse from date of
orchiectomy. To assess the relapse-predictive nature of our proposed model,
we calculated hazard ratios (HRs) using the Cox regression proportional
hazards model. A value of P < 0.05 was deemed statistically signiﬁcant for
multivariate modeling. Relapse-free survival (RFS) rates and incidence rates
were calculated using the Kaplan–Meier method and conditional risk ana-
lysis was carried out using varying times of origin (t0) at 0, 6, 12 and 18
months. Median time-to-relapse values were calculated after Cox regression
among patients who relapsed. Finally, for model diagnostic purposes, the
proportionality assumption was tested using Schoenfeld’s scaled residuals
and data goodness-of-ﬁt was assessed using Cox-Snell residuals.
results
patient characteristics
The cohort consisted of 135 patients with NSGCT and 131
patients with seminoma (n = 266). Patient characteristics are
described in Table 1. For NSGCT patients, there was no differ-
ence between LVI+ and LVI− in age, median follow-up time,
median time-to-ﬁrst surveillance scan, or surveillance metrics
Table 1. Patient characteristics and postorchiectomy surveillance
No. of patients Full cohort SGCT NSGCT NSGCT Pa NSGCT Pa
LVI+ LVI− EmbP+ EmbP−
N = 266 N = 131 N = 135 N = 22 N = 113 N = 55 N = 80
Median age at orchiectomy (range) 32 (17–66) 35 (17–66) 29 (17–64) 29 (18–60) 29 (17–64) 0.917 29 (18–55) 28 (17–64) 0.583
Median follow-up, months (range) 42 (1–264) 37 (1–264) 48 (2–222) 49 (9–163) 48 (2–222) 0.970 48 (3–174) 47 (2–222) 0.805
Surveillance metricsb n = 193 n = 103 n = 90 n = 15 n = 75 n = 37 n = 53
AP-CTs
Median time to first surveillance scan (range)c 5 (1–20) 6 (2–20) 6 (1–11) 6 (2–11) 4 (1–9) 0.090 5 (1–11) 4 (1–9) 0.520
Median # AP-CTs by 6 months (range) 1 (0–4) 0 (0–2) 1 (0–4) 0 (0–4) 1 (0–3) 0.265 1 (0–4) 1 (0–3) 0.389
Median # AP-CTs by 12 months (range) 3 (0–7) 1 (0–4) 2 (1–7) 2 (1–7) 2 (1–5) 0.378 2 (1–7) 2 (1–5) 0.703
Tumor markers
Median # TMs by 6 months (range) 1 (0–4) 1 (0–4) 3 (0–1) 2 (0–9) 4 (0–10) 0.450 3 (0–10) 3 (0–9) 0.967
Median # TMs by 12 months (range) 5 (0–16) 2 (0–8) 6 (1–16) 5 (1–13) 6 (2–16) 0.697 6 (1–12) 6 (2–16) 0.524
Surveillance visits
Median # SVs by 6 months (range) 2 (0–7) 0 (0–4) 3 (0–7) 2 (0–5) 3 (0–7) 0.741 3 (0–6) 3 (0–7) 0.833
Median # SVs by 12 months (range) 5 (0–12) 2 (0–7) 5 (0–12) 5 (1–8) 5 (0–12) 0.145 5 (0–12) 5 (1–11) 0.703
aNonparametric equality of medians test.
bThe ‘n’ value corresponds to the number of patients that had surveillance data available within each group.
cThe first surveillance scan is actually the second scan after orchiectomy. The first AP-CT is considered a baseline staging scan and hence not included in
surveillance regimen.
SGCT, seminoma; NSGCT, nonseminoma; LVI, lymphovascular invasion; EmbP, embryonal predominance; AP-CT, abdomino-pelvic computerized
tomography scan; TMs, tumor markers; SV, surveillance visit.
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(e.g. number of AP-CTs, TMs, visits). Similarly, no statistically
signiﬁcant difference was found between the EmbP+ and EmbP
− groups in age median follow-up time median time-to-ﬁrst
surveillance scan or surveillance metrics.
NSGCT risk score stratiﬁcation
Cox regression analysis was carried out to compare the RFS func-
tions from each NSGCT RF score category against the SGCT
group (Table 2) (RF0 neither LVI nor EmbP, RF1 one of either;
RF2 both present). We found a statistically signiﬁcant difference
for SGCT versus RF1, SGCT versus RF2 (P < 0.001, in both cases)
but not for SGCT versus RF0 (P = 0.108). Conditional risk sur-
vival analysis for each group using 0, 6, 12 and 18 months as
origin time (t0) found that RF0 and SGCT were not signiﬁcantly
different in any of the recorded time points, while RF1 and RF2
ceased to be signiﬁcantly different from SGCT at 12 and 18
months, respectively (Table 3) as most of the relapses happened
by month 12.
relapse patterns and relapse-free survival
Relapse patterns for NSGCT and SGCT patients are described
in Tables 4 and 5 and Figure 1. Fifty (37%) NSGCT and 20
(15%) SGCT patients relapsed. The median time-to-relapse was
11.5 versus 6.3 months for the SGCT and NSGCT groups, re-
spectively. For NSGCT, relapse incidence was highest in the ﬁrst
6-month interval (48% of all relapses) and the rate then progres-
sively declined (26% more by year 1; 12% more by year 2). For
SGCT, relapse incidence was highest in the second 6-month
interval (30% versus 20% during the ﬁrst 6 months), and then
declined (15% more by year 2). Seven of 50 (14%) relapses took
place after 2 years for NSGCT, compared with 7 of 20 (35%)
relapses for seminomas. Of the 85 NSGCT patients who had not
relapsed by year 5, 2.3% (2 of 85) subsequently relapsed. Of the
114 SGCT patients who had not relapsed by year 5, 2.6% (2 of
114) subsequently did.
For NSGCT patients, relapse rates were higher and median
time-to-relapse faster with increasing number of RFs: relapse rates
(%) and median time-to-relapse (months) were 25%/8.5 months,
41%/6.8 months and 78%/3.8months for RF0, RF1 and RF2, re-
spectively. Regarding disease-risk category at relapse, 94% of the
50 NSGCT relapses were classiﬁed as good-risk, while intermedi-
ate and poor-risk disease was found in two and one patients, re-
spectively—13 of the 14 RF2 patients who relapsed had good-risk
metastatic disease and one had intermediate-risk disease. All RF2
relapses occurred before 24 months. Of the 20 SGCT patients who
relapsed, only one of 20 did not present with good-risk disease.
discussion
GCT worldwide incidence has more than doubled in the last 40
years, especially in industrialized countries [14]. The advent of
successful salvage therapy, as well as the morbidity associated
with other postoperative management options, has made active
surveillance an acceptable management strategy [5]. In order to
decrease the potential lifetime attributable risk of cancer inci-
dence, modern surveillance regimens obtain fewer CTs, employ
techniques aimed at limiting radiation to the minimum neces-
sary for diagnostic purposes, or avoid altogether (i.e. MRI). The
wide implementation MRI surveillance may be limited by the
availability of appropriately experienced radiologists required to
achieve the same sensitivity as CTs, and is the subject of an
ongoing study [15].
Even with these modality improvements, active surveillance is
associated with signiﬁcant radiation exposure, which is particu-
larly relevant for the young GCT population. The safety of
decreasing the number of surveillance AP-CT scans for CS1
NSGCT patients was demonstrated by the Medical Research
Table 3. Conditional risk survival analysis by risk score categorya
Time point (months) Group HR (95% CI) Pa
0 RF0 1.67 (0.89–3.15) 0.108
RF1 3.35 (1.75–6.40) <0.001
RF2 9.80 (4.91–19.56) <0.001
6 RF0 1.33 (0.62–2.81) 0.463
RF1 2.35 (1.04–5.33) 0.040
RF2 5.76 (2.10–15.85) 0.001
12 RF0 1.44 (0.56–3.69) 0.446
RF1 1.25 (0.34–4.55) 0.736
RF2 4.60 (0.99–21.3) 0.051
18 RF0 1.57 (0.52–4.74) 0.426
RF1 1.78 (0.46–6.91) 0.404
RF2 3.67 (0.44–30.4) 0.228
aCox regression with SGCT as reference group. The assessment was
carried out at 0, 6, 12 and 18 months origin time points.
LVI, lymphovascular invasion; EmbP, embryonal predominance; RF0,
LVI− and EmbP−; RF1, LVI or EmbP+; RF2, LVI+ and EmbP+; HR,
hazard ratio; CI, confidence interval.
Table 2. NSGCT risk factor score and risk of relapse
No. of patients in group No. of relapsed patients (relapse rate) HR (95% CI) Pa
SGCT 131 20/131 (15%) 1.0 (ref) –
NSGCT RF0 76 19/76 (25%) 1.67 (0.89–3.15) 0.108
NSGCT RF1 41 17/41 (41%) 3.35 (1.75–6.40) <0.001
NSGCT RF2 18 14/18 (77%) 9.80 (4.91–19.56) <0.001
aCox regression analysis using SGCT as reference group.
SGCT, seminoma; NSGCT, nonseminoma; LVI, lymphovascular invasion; EmbP, embryonal predominance; RF0, LVI− and EmbP−; RF1, LVI or EmbP+;
RF2, LVI+ and EmbP+; HR, hazard ratio; CI, confidence interval.
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Table 5. Patterns of relapse
Groups Median time-to-
relapse (months)
Risk classification status at relapse Relapse after first-line
chemotherapy
Death secondary
to GCTGood Intermediate Poor
Full cohort (n = 266) 7.5 66/70 (95%) 3/70 (4%) 1/70 (1%) 7/70 (10%) 3/266 (1%)
SGCT (n = 131) 11.5 19/20 (95%) 1/20 (5%) – 2/20 (10%) 1/131 (1%)
NSGCT
All (50 relapsed) 6.3 47/50 (94%) 2/50 (4%) 1/50 (2%) 5/50 (10%) 2/135 (1%)
RF0 (19 relapsed) 8.5 17/19 (90%) 1/19 (5%) 1/19 (5%) 2/19 (10%) 1/135 (1%)
RF1 (17 relapsed) 6.8 17/17 (100%) – – 0 0
RF2 (14 relapsed) 3.8 13/14 (93%) 1/14 (7%) – 3/14 (21%) 1/135 (1%)
SGCT, seminomatous germ-cell tumor; NSGCT, nonseminomatous germ-cell tumor; GCT, germ-cell tumor; LVI, lymphovascular invasion; EmbP,
embryonal predominance; RF0, LVI− and EmbP−; RF1, LVI or EmbP+; RF2, LVI+ and EmbP+; HR, hazard ratio; CI, confidence interval.
Table 4. Relapse incidence and relapse-free survival
Groups Total relapses (rate) Cumulative relapse incidence
6 months 1 year 2 years 5 years 7 years
Full cohort (n = 266) 70/266 (26%) 28/70 (40%) 47/70 (67%) 56/70 (80%) 65/70 (93%) 69/70 (99%)
SGCT (n = 131) 20/131 (15%) 4/20 (20%) 10/20 (50%) 13/20 (65%) 17/20 (85%) 19/20 (95%)
NSGCT
All (n = 135) 50/135 (37%) 24/50 (48%) 37/50 (74%) 43/50 (86%) 48/50 (96%) 50/50 (100%)
RF0 (n = 76) 19/76 (25%) 7/19 (37%) 11/19 (58%) 14/19 (74%) 17/19 (89%) 19/19 (100%)
RF1 (n = 41) 17/41 (41%) 8/17 (47%) 14/17 (82%) 15/17 (88%) 17/17 (100%) 17/17 (100%)
RF2 (n = 18) 14/18 (78%) 9/14 (64%) 12/14 (86%) 14/14 (100%) 14/14 (100%) 14/14 (100%)
SGCT, seminomatous germ-cell tumor; NSGCT, nonseminomatous germ-cell tumor; LVI, lymphovascular invasion; EmbP, embryonal predominance;
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Figure 1. Kaplan–Meier relapse-free survival estimates.
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Council (MRC) randomized, controlled trial which randomized
400 patients to CT imaging at either 3 and 12 or 3, 6, 9, 12 and
24 months postorchiectomy [16]. It showed that there was no
appreciable increased risk of patients relapsing with intermedi-
ate or poor-prognosis disease in the 2 versus 5 scans when
patients were also surveyed with frequent plain chest radio-
graphs and blood TMs. The currently employed surveillance
regimen leads to signiﬁcant radiation exposure with as many as
12 AP-CTs within the ﬁrst 5-year period for NSGCT patients
[13]. This number of CT scans typically leads to radiation
exposure surpassing the established 5-year 100 mSv cumulative
radiation exposure limit. Aiming to minimize the radiation
exposure burden associated with active surveillance, we sought
to identify low-risk NSGCT patient subsets whose relapse risk
would not be affected by less frequent CT scanning.
We selected LVI and EmbP to be the main constituents of the
NSGCT risk score given that several prior reports have shown
that EmbP and LVI together portend a higher risk of relapse
than either one alone, although EmbP’s prognostic signiﬁcance
is still actively debated [12, 17, 18]. The EmbP deﬁnition avoids
the exclusion of patients with substantial embryonal cell cancer
which may still lead to an increased risk of recurrence (30%–
40%) [19] as the alternate deﬁnition (>50% cutoff value) fails to
incorporate cases in which the embryonal component predomi-
nates such as mixed tumors with multiple tissue subtypes with
40%/30%/30% distributions. Additionally, by assessing EmbP in
conjunction with LVI, avoidance of an effect of LVI status upon
EmbP status might be avoided [12].
Both the LVI+/LVI− and EmbP+/EmbP− had similar follow-
up time intervals, days to ﬁrst surveillance scan and number of
AP-CTs, TMs and visits. Furthermore, the relapse rates obtained
in our study are consistent with what has been previously
reported for SGCT [20] and NSGCT [6].
We found that the RF score was proportional to relapse rate,
incidence rate and cumulative incidence but inversely propor-
tional to RFS and median time-to-relapse. It is of note that we
found the RFS for SGCT and NSGCT with neither EmbP nor
LVI (RF0) were similar. Cox regression analysis conﬁrmed that
their RFS functions were not statistically different at all time
points (including t0 = 0 months). Conditional risk analysis
revealed that the absolute and relative relapse probability for all
groups was highest during the ﬁrst 6-month period and progres-
sively decreased thereafter. However, analysis beyond the 1-year
time point should be carefully interpreted due to the small
sample sizes (particularly on the RF1/RF2) and the resulting loss
of statistical power.
Recent work by Kollsmannsberger et al. suggests the plausibility
of optimizing surveillance schedules by risk-stratifying patients
by LVI status [21]. Our study offers an opportunity to further
reﬁne these schemes by showing that EmbP may be predictive of
relapse when considered in conjunction with LVI. Although this
retrospective study is not intended to change practice, it aims to
support a prospective evaluation of these ﬁndings along with
craniocaudal lymph node assessment, as well as other potential
novel pathological/ molecular biomarkers and their inﬂuence on
relapse occurrence and timing.
In summary, we found that the risk stratiﬁcation of NSGCT
patients into a risk score system based on EmbP and LVI yielded
three groups with signiﬁcantly different RFS functions. The
lowest risk group (RF0) behaved similarly to SGCT in terms of
time-to-relapse for all recorded time points, while RF1 and RF2
joined them at 12 and 18 months, respectively. Our work sup-
ports the notion that the surveillance regimen for NSGCT
RF0 may be optimized to resemble that of SGCT patients.
Additionally, it is consistent with Kollmannsberger’s study but
supports utilizing EmbP and LVI status to further risk-stratify
patients in order to optimize surveillance regimens.
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Background: Platinum-based two-drug combination chemotherapy has been standard of care for patients with
advanced nonsmall-cell lung cancer (NSCLC). The primary aim was to compare overall survival (OS) of patients with
advanced NSCLC between the two chemotherapy regimens. Secondary end points included progression-free survival
(PFS), response, safety, and quality of life (QoL).
Patients and methods: Patients with previously untreated stage IIIB or IV NSCLC, an Eastern Cooperative Oncology
Group performance status of 0–1 and adequate organ function were randomized to receive either oral S-1 80 mg/m2/day
on days 1–21 plus cisplatin 60 mg/m2 on day 8 every 4–5 weeks, or docetaxel 60 mg/m2 on day 1 plus cisplatin 80 mg/m2
on day 1 every 3–4 weeks, both up to six cycles.
Results: A total of 608 patients from 66 sites in Japan were randomized to S-1 plus cisplatin (n = 303) or docetaxel plus
cisplatin (n = 305). OS for oral S-1 plus cisplatin was noninferior to docetaxel plus cisplatin [median survival, 16.1 versus
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